

## **SB 1528 -2, -3 STAFF MEASURE SUMMARY**

### **Senate Committee On Health Care**

---

**Prepared By:** Daniel Dietz, LPRO Analyst

**Meeting Dates:** 2/11

---

#### **WHAT THE MEASURE DOES:**

Directs the Oregon Health Authority to study health care.

*Fiscal impact: fiscal impact issued, has minimal fiscal impact.*

*Revenue impact: revenue impact issued, has no revenue impact.*

#### **ISSUES DISCUSSED:**

##### **EFFECT OF AMENDMENT:**

-2 Replaces the measure. Expands annual drug manufacturer requirements to include information about all patient assistance programs, including the number of Oregon consumers who participated, eligibility criteria, the total value of assistance, and other specified information. Becomes operative on January 1, 2028.

-3 Replaces the measure. Changes the operative date for requirements for nurse staffing ratios as provided under ORS 441.765 to July 1, 2027.

#### **BACKGROUND:**

Drug manufacturers serving Oregon consumers make annual reports to the Department of Consumer and Business Services (DCBS), including price information about drugs exceeding specified thresholds for price of monthly supply (\$100) and for change in price (ten percent). [ORS 646A.689](#). For drugs that meet or exceed specified thresholds, manufacturers are required to report on patient assistance program (PAP) participation, eligibility, and the total value of assistance. In its [2025 report](#) to the Legislative Assembly, Oregon's Prescription Drug Price Transparency Report recommends extending requirements for PAP reporting to all PAPs in which Oregon consumers participate.

Senate Bill 1528-2 would require all drug manufacturers with patient assistance programs serving Oregon consumers to report annually to the Department of Consumer and Business Services beginning January 1, 2028.